Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07282600 · ClinicalTrials.gov registry record · Phase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 3
Development phase
1,035
Enrollment target
20
Study locations

NCT07282600 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 1,035 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07282600, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 3
Development phase
1,035 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

Conditions Studied

Obesity Overweight

Interventions

  • DRUG Placebo
  • DRUG Eloralintide

Study Locations (20)

California

  • San Fernando Valley Health Institute - Canoga Park
  • AMCR Institute - Escondido
  • NorCal Medical Research, Inc - Greenbrae
  • Inglewood Clinical - Inglewood
  • Ark Clinical Research - Long Beach
  • Pacific Clinical Studies - Los Alamitos
  • Care Access - Santa Clarita - Santa Clarita
  • Encompass Clinical Research - Spring Valley
  • Diablo Clinical Research, Inc. - Walnut Creek

Florida

  • Arrow Clinical Trials - Daytona Beach
  • Care Access - Delray Beach - Delray Beach
  • Fleming Island Center for Clinical Research - Fleming Island
  • Nature Coast Clinical Research - Inverness - Inverness
  • Jacksonville Center for Clinical Research - Jacksonville

Alabama

  • Birmingham Clinical Research - Birmingham
  • Cullman Clinical Trials - Cullman

Connecticut

  • New England Research Associates, LLC - Bridgeport
  • CMR of Greater New Haven, LLC - Hamden

Arizona

  • Tucson Clinical Research Institute - Tucson

Colorado

  • Care Access - Aurora - Aurora

Trial Details

FieldValue
Enrollment Target 1,035 participants
Start Date 2025-12-15
Est. Completion 2028-02
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07282600

The ClinicalTrials.gov registry entry for NCT07282600 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,035 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (27% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07282600 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT07282600 about?

NCT07282600 is a clinical study titled "A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes". The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

What is the current status of trial NCT07282600?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,035 participants. The study started on 2025-12-15. Estimated completion is 2028-02.

What conditions does trial NCT07282600 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT07282600?

The interventions under investigation include: Placebo (DRUG), Eloralintide (DRUG).

Who is sponsoring clinical trial NCT07282600?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07282600 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.